



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 007 717 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (51) Int Cl.:
C12N 15/86 (2006.01) **A61K 48/00** (2006.01)
C12N 5/10 (2006.01)
- (48) Corrigendum issued on:
03.05.2006 Bulletin 2006/18
- (86) International application number:
PCT/US1998/017606
- (45) Date of publication and mention
of the grant of the patent:
18.01.2006 Bulletin 2006/03
- (87) International publication number:
WO 1999/010516 (04.03.1999 Gazette 1999/09)
- (21) Application number: **98944526.7**
- (22) Date of filing: **25.08.1998**

(54) **METHODS AND COMPOSITIONS FOR CANCER THERAPIES USING GENES ENCODING INTERFERON-BETA**

VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DIE KREBSTHERAPIE UNTER VERWENDUNG VON INTERFERON-BETA CODIERENDEN GENEN

METHODES ET COMPOSITIONS DESTINEES AUX THERAPIES CONTRE LE CANCER UTILISANT DES GENES CODANT POUR L'INTERFERON-BETA

- | | |
|--|---|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI</p> <p>(30) Priority: 29.08.1997 US 57254 P</p> <p>(43) Date of publication of application:
14.06.2000 Bulletin 2000/24</p> <p>(60) Divisional application:
06000842.2</p> <p>(73) Proprietor: Biogen Idec MA Inc.
Cambridge, Massachusetts 02142 (US)</p> <p>(72) Inventors:
• BARSOUM, James, G.
Lexington, MA 02173 (US)
• QIN, Xiao-Qiang
Winchester, MA 01890 (US)</p> <p>(74) Representative: Vossius & Partner
Siebertstrasse 4
81675 München (DE)</p> | <p>(56) References cited:
EP-A- 0 707 071 WO-A-97/32991</p> <ul style="list-style-type: none">• JIAN-FENG ZHANG ET AL: "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 93, April 1996, pages 4513-4518, XP002093893 WASHINGTON US cited in the application• B. HOWARD ET AL: "Retrovirus-mediated gene transfer of the human gamma-IFN gene: A therapy for cancer" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 716, 31 May 1994, pages 167-187, XP002093894• ENGELHARDT J F ET AL: "PROLONGED TRANSGENE EXPRESSION IN COTTON RAT LUNG WITH RECOMBINANT ADENOVIRUSES DEFECTIVE IN E2A" HUMAN GENE THERAPY, vol. 5, no. 10, 1 October 1994, pages 1217-1229, XP000574007 cited in the application |
|--|---|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 007 717 B8

- J.L. BRAMSON ET AL: "Direct intratumoral injection of an adenovirus expressing Interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of Interleukin-12" HUMAN GENE THERAPY , vol. 7, 20 October 1996, pages 1995-2002, XP002093895
- ZHANG J F ET AL: "GENE THERAPY WITH AN ADENO-ASSOCIATED VIRUS CARRYING AN INTERFERON GENE RESULTS IN TUMOR GROWTH SUPPRESSION AND REGRESSION" CANCER GENE THERAPY, vol. 3, no. 1, January 1996, pages 31-38, XP002038701
- YAGI K ET AL: "INTERFERON-BETA ENDOGENOUSLY PRODUCED BY INTRATUMORAL INJECTION OF CATIONIC LIPOSOME-ENCAPSULATED GENE: CYTOCIDAL EFFECT ON GLIOMA TRANSPLANTED INTO NUDE MOUSE BRAIN" BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, vol. 32, no. 1, January 1994, pages 167-171, XP002047795
- S.M. FREEMAN ET AL: "The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified" CANCER RESEARCH., vol. 53, 1 November 1993, pages 5274-5283, XP002093896 MD US
- SETOGUCHI Y ET AL: "EX VIVO AND IN VIVO GENE TRANSFER TO THE SKIN USING REPLICATION- DEFICIENT RECOMBINANT ADENOVIRUS VECTORS" JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 102, no. 4, April 1994, pages 415-421, XP002044071
- E.M. TOLOZA ET AL: "Transduction of murine and human tumors using recombinant Adenovirus vectors" ANNALS OF SURGICAL ONCOLOGY, vol. 4, no. 1, January 1997, pages 70-79, XP002093897
- QIN XQ. ET AL: "Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune deficient mice" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 95, no. 24, 24 November 1998, pages 14411-14416, XP002093898 WASHINGTON US
- K. XIE ET AL: "Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-beta gene: Possible role of Nitric Oxide" CLINICAL CANCER RESEARCH, vol. 3, no. 12pt.1, December 1997, pages 2283-2294, XP002093899
- ASSELBERGS F. ET AL J. MOL. BIOL. vol. 163, 1983, pages 177 - 207
- BRIDGE E.; KETNER G. J. OF VIROLOGY vol. 63, no. 2, February 1989, pages 631 - 638